Characterization of diethylnitrosamine-induced liver carcinogenesis in Syrian golden hamsters

  • Authors:
    • Guo Chen
    • Zhi-Kai Dai
    • Rong-Gan Liang
    • Sheng-Jun Xiao
    • Song-Qing He
    • Hai-Lu Zhao
    • Qing Xu
  • View Affiliations

  • Published online on: December 2, 2011     https://doi.org/10.3892/etm.2011.406
  • Pages: 285-292
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of this study was to characterize hepato­carcinogenesis in diethylnitrosamine (DEN)-treated hamsters. Syrian golden hamsters (n=36) were administered DEN by hypodermic injection and addition to drinking water. Morphological analyses, including light microscopy and immunohistochemistry of α-fetal protein (AFP), were performed on liver and lung tissues. Primary cell culture and tumor transplantation were carried out to evaluate the potential application in hepatocellular carcinoma (HCC) research. From 25 to 50 weeks of treatment, liver tumors, including macronodular HCC and ascites, were found in one-third (4/12) of the animals treated with DEN. HCC was characterized by poor differentiation, frequent mitosis, AFP reaction, vessel invasion and potential application in primary cell culture and xenotransplantation. Pre-neoplastic lesions were hyperplastic nodules comprised of clear cells, bile duct proliferation, fatty metamorphosis and multilocular cysts. The DEN-treated hamsters also showed lung tumors consisting of AFP-negative, well-differentiated neoplastic cells. Characterization of DEN-induced HCC in hamsters provides insights into human hepatocarcinogenesis. This animal model has potential applications in HCC research.

Introduction

Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third most common cause of cancer-related death in the world (1,2). The number of new HCC cases is estimated to be 564,000 per year, including 398,000 men and 166,000 women (3). It accounts for 80% of all human liver cancers, and is responsible for 0.5–1 million worldwide deaths annually (4). The rising incidence and poor prognosis of HCC cases have prompted extensive research on its pathogenesis for a better understanding of HCC development.

Toxic industrial chemicals, air and water pollutants, food additives and fungal toxins are major sources of hepatocarcinogenesis (5). Although these agents have been suspected, the molecular pathogenesis of HCC remains unclear. As an established environmental hepatocarcinogen, diethylnitrosamine (N-nitrosodiethylamine; DEN), which produces primary metabolic activation resulting in initiation of liver carcinogenesis (6) and formation of liver tumors after repeated administration, is normally used to induce liver cancer in several animal models (7,8). DEN-induced hepatocarcinoma in animals serves as a standard model to study the beneficial effects of many drugs and treatments on HCC (9,10). Prior studies have shown the histopathological similarities of human HCC and chemical-induced experimental liver tumors in Wistar rats and Syrian golden hamsters (11). The purpose of this study was to define the characterization of DEN-induced liver carcinogenesis in Syrian golden hamsters.

Materials and methods

Chemical reagents

DEN was purchased from Sigma (St. Louis, MO, USA) and freshly diluted in saline to a final concentration before use.

Animals

A total of 36 male Syrian hamsters (Slike Experimental Animal Company, Shanghai, China) at 3 weeks of age and weighing 75–100 g, were housed in accordance with the institutional guidelines for animal experimentation and maintained under standard laboratory conditions with a room temperature of 23±2°C, relative humidity of 60±5% and a 12 h/12 h light/dark cycle. All animals were fed with a standard diet and water ad libitum.

The hamsters were divided into two groups. Hamsters (n=12) injected with normal saline and who drank distilled water were used as control. Model hamsters (n=24) received DEN. DEN was injected subcutaneously twice per week for 15 weeks, followed by withdrawal and normal feeding at 16–24 weeks. From 25 to 40 weeks, DEN was added to the drinking water with an initial concentration of 0.05 g/l at 26 weeks and a final concentration of 0.1 g/l until 40 weeks. Normal drinking resumed from 41 to 50 weeks (Fig. 1A). Two animals from each group were sacrificed at 15, 24 and 45 weeks for histopathological examination. All hamsters were sacrificed by the end of 50 weeks (Fig. 1A).

Histopathological examination

Animals were weighed weekly during the treatment period and monthly thereafter. At the end of the 50th week, all surviving animals were sacrificed with 1% sodium pentobarbital. Liver, lung, spleen, kidney and heart were examined grossly and microscopically for DEN-induced tumorigenicity. The organs were fixed in 10% phosphate-buffered formalin and processed for histological examination with H&E staining. H&E-stained sections from multiple paraffin blocks (16 per animal) for each period were examined by light microscopy. All nodular lesions were diagnosed histopathologically and counted using serial sections.

Immunohistochemical staining

Tissues were fixed in 10% phosphate-buffered formalin and processed for α-fetoprotein (AFP) (Envison kit; Maixin-Bio Company, Fuzhou, China). AFP immunostaining was performed according to the steps described in the operational manuals. Dilution of the primary antibody was 1:50. Human AFP-positive HCC tissue served as the positive control, while the negative control was diluted with normal mouse serum in PBS solution as a replacement for the primary antibody control.

Cell culture and tumor transplantation

The isolated tissue was immediately minced (1 mm3) by scalpel under sterile conditions and incubated with 1 mg/ml collagenase IV (C5138; Sigma) for 30 min at 37°C under gentle agitation (Sanyo, Japan) as previously described (12). Next, the cells were passed through a 200-mesh screen and washed twice before spinning at 1,500 rpm for 5 min at 4°C. Cells were cultured in a culture flask (Corning) in DMEM/F12 medium (Hyclone, Beijing, China) with the addition of 10% fetal bovine serum (Gibco), 100 IU/ml penicillin (Amresco) and 50 μg/ml streptomycin (Amresco). The cell culture was monitored with phase contrast microscopy.

Tumor tissue with high proliferating activity was selected under sterile conditions, rinsed with iced normal saline three times and cut into small pieces of 1×1 mm for xenografts. Under direct vision through surgery, a small piece of tumor tissue prepared within 2 h was inoculated in the left lobe of the liver of male Syrian hamster, and sutured and disinfected conventionally. Caesarean section was performed for observation at 7 and 10 days after transplantation (Nikon ECLIPSE TS100).

Statistical analysis

All of the data were processed by statistical software SPSS 16.0. Results were expressed as the means ± SE. Statistical analysis was tested using one-way analysis of variance. Differences were considered to denote statistical significance at two-tailed p<0.05.

Results

Macronodular hepatocellular carcinoma in Syrian hamsters

Fig. 1B shows the survival rate of hamsters. A total of 6 animals treated with DEN died between 45 and 50 weeks, whereas unexpected death was not observed in the control hamsters.

No tumors were observed in the control animals. The gross pathological findings of DEN-treated livers included ascites, hepatomegaly, small hepatic cysts and multiple hepatic nodules. Gross examination at 45 and 50 weeks of the DEN treatment demonstrated macronodular HCC in 33.3% (4/12) of the DEN-treated Syrian hamsters (Fig. 2). The livers with HCC were enlarged with multiple small nodules of 0.2–0.5 cm in diameter (Fig. 2A–D), or with a single large nodule of 3 cm in diameter (Fig. 2E). Light microscopy and H&E staining showed nodular HCC (Fig. 3A). There were frequent bizarre neoplastic cells and abnormal mitotic figures (Fig. 3B). In addition, the HCC nodules were accompanied by chronic inflammatory infiltrates (Fig. 3A) and separated by cords of atrophic hepatocytes (Fig. 3A).

We also observed the invasiveness of macronodular HCC (Fig. 4). Invasion of blood vessels (Fig. 4A) and lymph vessels (Fig. 4B) by HCC was evident in hamsters treated with DEN for 45 weeks and onwards. The blood vessels showed congestion, whereas the lymph vessels were markedly dilated with multiple cystic changes. Immunohistochemical staining revealed that approximately one-third of the HCC cells were positive for AFP (Fig. 5), and the immunoreactivity was localized in the cytoplasm and membrane.

Primary cell culture and tumor transplantation

The use of primary cultures from tumor cells is a promising approach for the development of new methods for the diagnostics and therapy of cancer. Fig. 6 illustrates the cultured HCC cells on day 1 (Fig. 6A), day 3 (Fig. 6B) and day 7 (Fig. 6C and D). Clone expansion and confluence was time-dependent in this primary cell culture.

Pre-neoplastic changes in the liver

Changes in the DEN-treated livers in addition to HCC were chronic inflammatory cell infiltrates, fatty metamorphosis, ballooning degeneration, focal eosinophilic necrosis, hyperplastic nodules and multilocular cysts (Figs. 710). Cirrhosis and dilatation of the common bile duct were not observed in any animals.

From 15 weeks onward, DEN-treated animals showed chronic inflammatory infiltrates, dilated lymph vessels and proliferating bile ducts in the portal area (Fig. 7A). In addition, fatty change and clustering of proliferative bile ducts were found adjacent to the central vein (Fig. 7B). Hepatocytes in the DEN-treated hamsters also underwent degenerative changes, such as nuclear vacuolation, ballooning degeneration (Fig. 7C) and eosinophilic necrosis (Fig. 7D).

Nodular hyperplasia and hyperplastic nodules were encountered in the hamsters at 16–24 weeks of the DEN treatment (Fig. 8). The size of the nodular lesions varied from a pinpoint to 1.5 cm in diameter. The nodular lesions included patches of clear cell hyperplasia coexisting with dilated blood vessels (Fig. 8A), focal clear cell hyperplasia accompanying proliferating bile ducts and chronic inflammatory cells adjacent to the central vein (Fig. 8B), and well-defined nodular hyperplasia arising from the background of chronic inflammation and hepatocyte degeneration (Fig. 8C). In addition, clear cell nodules and focal clustering of microcysts often existed (Fig. 8D).

At 25–50 weeks of the DEN treatment, there were focal bile duct hyperplasia (Fig. 9) and fatty changes (Fig. 10) adjacent to HCC lesions. Focal bile duct dysplasia, with marked dilation and cystic formation (Fig. 9A), fatty changes (Fig. 9B), congestion (Fig. 9C) and clear cell hyperplasia (Fig. 9D), often co-existed. Fatty changes were observed in both early (Fig. 10A) and advanced (Fig. 10B) stage of HCC, suggesting an association between fatty metamorphosis and the hepatic carcinogenesis liver.

Lung tumors

Gross and microscopic examination revealed lung tumors in 2/4 hamsters at 25–50 weeks of the DEN treatment. The lung tumor mass was most frequently single rather than multiple, and varied from 0.3 to 1.2 cm in diameter. Light microscopy and H&E staining demonstrated well-differentiated neoplastic cells (Fig. 11A) admixed with chronic inflammatory cell infiltrates (Fig. 11B). The morphology of the neoplastic cells in the lung was different compared to that of HCC. Consistently, immunohistochemistry illustrated that only a few macrophages, but not the neoplastic cells, were positive for AFP (Fig. 12), indicating that the lung tumors may not be HCC metastasis. No tumors were detected in the kidney, pancreas, spleen or other anatomical sites.

Discussion

This study describes the histopathological series of events in hamsters administered DEN. The most important findings were macronodular HCC with a potential for primary cell culture and tumor transplantation, pre-neoplastic lesions that progress to HCC and primary lung tumors.

HCC is a highly malignant tumor with poor prognosis (13,14). Advanced HCC is associated with wasting symptoms, such as ascites and weight loss (15). One of the biochemical characteristics of HCC is AFP elevation (1618). Pre-neoplastic lesions, such as fatty change and nodular hyperplasia, are frequently observed in HCC in both early and advanced stages (19). DEN is an established environmental hepatocarcinogen initially used to induce liver cancer in animal models (20). It has been shown that on primary metabolic activation, DEN produces the promutagenic adducts, O6-ethyl deoxy guanosine and O4- and O6-ethyl deoxy thymidine that causes DNA-chain damage and miscode gene sequences, paving the way to initiation of liver carcinogenesis (6,21). In DEN-treated hamsters, progressive body weight loss, hepatomegaly, ascites and tumor formation are noted (22). The DEN-induced macronodular HCC was characterized by poor differentiation, AFP immunoreativity, vessel invasion and a potential application for primary cell culture and tumor transplantation. These findings indicate that administration of DEN produces HCC in hamsters that mimics human HCC (2328).

Primary human HCC exhibits characteristics, such as arterial phase hypervascularity with portal phase washout, and the presence of fatty degeneration and portal venous invasion. Intrahepatic biliary duct dilatation is well recognized with cholangiocarcinoma and is frequently observed in metastatic HCC (29). HCC is frequently accompanied by dilatation of the intrahepatic bile ducts (3037), while focal bile duct hyperplasia often occurs in the adjacent non-tumorous liver tissue of European patients (38). In this study, pre-neoplastic lesions, including focal bile duct hyperplasia, fatty change and clear cell hyperplasia, occurred in DEN-induced hepatocarcinogenesis.

In the present study, lung neoplastic cells were morphologically distinct from HCC and had negative AFP reactivity, indicating that the lung tumors were more likely primary lesions rather than metastases. This finding is consistent with an early report that feeding of DEN induces tumors of the lung and liver in rats (39). To our knowledge, this is the first report of lung tumors in DEN-treated hamsters.

In this study, DEN-induced hepatocarcinogenesis progressed over specific periods. A toxic reaction and hepatocyte regeneration occurred in the early stage defined from the 1st to 15th week of treatment. This was followed by prominent nodular hyperplasia and fatty changes from 16 to 24 weeks of administration. From 25 to 50 weeks of induction, both micronodular and macronodular HCC occurred. These serial events are consistent with the development of human hepatocarcinogenesis (40), highlighting the potential application of this animal model for HCC research.

In the present study, dose-response effects were not tested, since long-term treatment with DEN results in the substantial loss of animals. On the other hand, the greater susceptibility of animals toward a carcinogenic effect seems well documented, but the underlying mechanism remains undetermined. In summary, DEN induces hepatocarcinogenesis in hamsters and may serve as a new and dynamic animal model for studying the pathogenesis and clinical treatment of hepatocellular carcinoma.

Acknowledgements

This study was in part supported by the National Natural Science Foundation of China (no. 30760281), a direct grant from the Guilin Medical College, and by a Guangxi Medical Science Experimental Center open fund for special projects (KFJJ2010-49).

References

1. 

J FerlayHR ShinF BrayD FormanC MathersDM ParkinEstimates of worldwide burden of cancer in 2008: Globocan 2008Int J Cancer12728932917201010.1002/ijc.2551621351269

2. 

L HerszenyiZ TulassayEpidemiology of gastrointestinal and liver tumorsEur Rev Med Pharmacol Sci14249258201020496531

3. 

M ShermanHepatocellular carcinoma: epidemiology, risk factors, and screeningSemin Liver Dis25143154200510.1055/s-2005-87119415918143

4. 

PA FaraziRA DePinhoHepatocellular carcinoma pathogenesis: from genes to environmentNat Rev Cancer6674687200610.1038/nrc193416929323

5. 

P JananiK SivakumariA GeethaB RavisankarC ParthasarathyChemopreventive effect of bacoside a on n-nitrosodiethylamine-induced hepatocarcinogenesis in ratsJ Cancer Res Clin Oncol136759770201010.1007/s00432-009-0715-019916024

6. 

L VernaJ WhysnerGM WilliamsN-nitrosodiethylamine mechanistic data and risk assessment: bioactivation, DNA-adduct formation, mutagenicity, and tumor initiationPharmacol Ther715781199610.1016/0163-7258(96)00062-98910949

7. 

XE LiuS DewaeleV VanhoorenYD FanL WangJ van HuysseH ZhuangR ContrerasC LibertCC ChenAlteration of n-glycome in diethylnitrosamine-induced hepatocellular carcinoma mice: a non-invasive monitoring tool for liver cancerLiver Int3012211228201010.1111/j.1478-3231.2010.02279.x20524982

8. 

AK MandalS DasM MitraRN ChakrabartiM ChatterjeeN DasVesicular flavonoid in combating diethylnitrosamine induced hepatocarcinoma in a rat modelJ Exp Ther Oncol7123133200818771086

9. 

VG BychkovLS TrukhanovaGG KrylovLN KulikovaED Mal’tsevaEA SmirnovaVF KondalenkoN-nitrosodiethylamine-induced changes in the liver of syrian hamster with superinvasive opistorchiasisVopr Onkol494764832003(In Russian).

10. 

R SimonsenMA VirjiInterpreting the profile of liver-function tests in pediatric liver transplantsClin Chem301607161019846148160

11. 

A Llombart BoschA Peydro OlayaUltrastructure of human hepatic carcinomas compared with ultrastructural findings in hepatomas induced by chemical agents in Wistar rats and the Golden hamsterRev Esp Oncol302873021983(In Spanish).

12. 

AC FluckigerG MarcyM MarchandD NegreFL CossetS MitalipovD WolfP SavatierC DehayCell cycle features of primate embryonic stem cellsStem Cells24547556200610.1634/stemcells.2005-019416239321

13. 

M Di MaioE De MaioF PerroneS PignataB DanieleHepatocellular carcinoma: systemic treatmentsJ Clin Gastroenterol35S109S114200212394214

14. 

AS YuEB KeeffeManagement of hepatocellular carcinomaRev Gastroenterol Disord38242003

15. 

MC KweTumors of the liverHepatology – A Text Book of Liver DiseaseD ZakimTD BoyerSaundersPhiladelphia151315481996

16. 

JJ LokichDetermination of response in treatment of hepatic neoplasiaSemin Oncol1022823719836867753

17. 

F RosiA TabucchiF CarlucciP GalieniF LauriaL ZanoniR GuerrantiE MarinelloR Pagani5′-nucleotidase activity in lymphocytes from patients affected by B-cell chronic lymphocytic leukemiaClin Biochem312692721998

18. 

S SellFF BeckerAlpha-fetoproteinJ Natl Cancer Inst6019261978

19. 

R KutamiY NakashimaO NakashimaK ShiotaM KojiroPathomorphologic study on the mechanism of fatty change in small hepatocellular carcinoma of humansJ Hepatol33282289200010.1016/S0168-8278(00)80369-410952246

20. 

M KawabeC LinN KimotoM SanoM HiroseT ShiraiModifying effects of propolis on MeiQx promotion of rat hepatocarcinogenesis and in a female rat two-stage carcinogenesis model after multiple carcinogen initiationNutr Cancer37179186200010.1207/S15327914NC372_10

21. 

MLZ DagliAgentes antineoplasicosFarmacologia Aplicada á Medicina Veterinaria3rd editionHS SpinosaSL GorniakMM BernardiEditora Guanabara-KooganSão PauloBrasil5776082002

22. 

HC PitotHA CampbellR MaronpotN BawaTA RizviYH XuL SargentY DraganM PyronCritical parameters in the quantitation of the stages of initiation, promotion, and progression in one model of hepatocarcinogenesis in the ratToxicol Pathol1759461219892697939

23. 

T KalinskiA RoessnerHepatocellular carcinoma: pathology and liver biopsyDig Dis27102108200910.1159/00021834119546547

24. 

SR PrasadH WangH RosasCO MeniasVR NarraWD MiddletonJP HeikenFat-containing lesions of the liver: radiologic-pathologic correlationRadiographics25321331200510.1148/rg.25204508315798052

25. 

T RoskamsM KojiroPathology of early hepatocellular carcinoma: conventional and molecular diagnosisSemin Liver Dis301725201010.1055/s-0030-124712920175030

26. 

M SakamotoS HirohashiY ShimosatoEarly stages of multistep hepatocarcinogenesis: adenomatous hyperplasia and early hepatocellular carcinomaHum Pathol22172178199110.1016/0046-8177(91)90039-R

27. 

K ShirabeT MotomuraJ MutoT ToshimaR MatonoY ManoK TakeishiH IjichiN HaradaH UchiyamaT YoshizumiA TaketomiY MaeharaTumor-infiltrating lymphocytes and hepatocellular carcinoma: pathology and clinical managementInt J Clin Oncol15552558201010.1007/s10147-010-0131-020963618

28. 

A VillanuevaY HoshidaC BattistonV TovarD SiaC AlsinetH CornellaA LiberzonM KobayashiH KumadaSN ThungJ BruixP NewellC AprilJB FanS RoayaieV MazzaferroME SchwartzJM LlovetCombining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinomaGastroenterology14015011512201110.1053/j.gastro.2011.02.00621320499

29. 

KS JhaveriJ HalankarD AguirreM HaiderG LockwoodM GuindiS FischerIntrahepatic bile duct dilatation due to liver metastases from colorectal carcinomaAJR Am J Roentgenol193752756200910.2214/AJR.08.218219696289

30. 

M JinzakiA TanimotoK SuzukiT SekiY SatohK HiramatsuM MukaiI NakanishiLiver metastases from colon cancer with intra-bile duct tumor growth: Radiologic featuresJ Comput Assist Tomogr21656660199710.1097/00004728-199707000-000279216779

31. 

M KojiroK KawabataY KawanoF ShiraiN TakemotoT NakashimaHepatocellular carcinoma presenting as intrabile duct tumor growth: a clinicopathologic study of 24 casesCancer4921442147198210.1002/1097-0142(19820515)49:10%3C2144::AID-CNCR2820491026%3E3.0.CO;2-O6280834

32. 

NW LeeKP WongKF SiuJ WongCholangiography in hepatocellular carcinoma with obstructive jaundiceClin Radiol35119123198410.1016/S0009-9260(84)80008-26321083

33. 

K OkanoJ YamamotoY MoriyaT AkasuT KosugeM SakamotoS HirohashiMacroscopic intrabiliary growth of liver metastases from colorectal cancerSurgery126829834199910.1016/S0039-6060(99)70022-X10568181

34. 

K OkanoJ YamamotoT OkabayashiY SugawaraK ShimadaT KosugeS YamasakiH FurukawaY MuramatsuCt imaging of intrabiliary growth of colorectal liver metastases: a comparison of pathological findings of resected specimensBr J Radiol75497501200210.1259/bjr.75.894.75049712124235

35. 

P SoyerA SibertJP LaissyIntrahepatic bile duct dilatation secondary to hepatocellular carcinoma: Ct features in 10 patientsAbdom Imaging20114117199510.1007/BF002015167787711

36. 

S TakamatsuK TeramotoT KawamuraA KudoN NoguchiT IrieT OchiaiJ KumagaiM KoikeS AriiLiver metastasis from rectal cancer with prominent intrabile duct growthPathol Int54440445200410.1111/j.1440-1827.2004.01636.x15144404

37. 

E van SonnenbergJT Ferrucci JrBile duct obstruction in hepatocellular carcinoma (hepatoma) – clinical and cholangiographic characteristics. Report of 6 cases and review of the literatureRadiology1307131979

38. 

Z SchaffCC HsiaI SarosiE TaborOverexpression of transforming growth factor-alpha in hepatocellular carcinoma and focal nodular hyperplasia from European patientsHum Pathol25644651199410.1016/0046-8177(94)90296-88026823

39. 

KM HerroldLJ DunhamInduction of tumors in the syrian hamster with diethylnitrosamine (N-nitrosodiethylamine)Cancer Res23773777196313954107

40. 

CY LeeYC HsuJY WangCC ChenJH ChiuChemopreventive effect of selenium and chinese medicinal herbs on n-nitrosobis(2-oxopropyl)amine-induced hepatocellular carcinoma in syrian hamstersLiver Int28841855200810.1111/j.1478-3231.2008.01698.x18346132

Related Articles

Journal Cover

February 2012
Volume 3 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Chen G, Dai Z, Liang R, Xiao S, He S, Zhao H and Xu Q: Characterization of diethylnitrosamine-induced liver carcinogenesis in Syrian golden hamsters. Exp Ther Med 3: 285-292, 2012.
APA
Chen, G., Dai, Z., Liang, R., Xiao, S., He, S., Zhao, H., & Xu, Q. (2012). Characterization of diethylnitrosamine-induced liver carcinogenesis in Syrian golden hamsters. Experimental and Therapeutic Medicine, 3, 285-292. https://doi.org/10.3892/etm.2011.406
MLA
Chen, G., Dai, Z., Liang, R., Xiao, S., He, S., Zhao, H., Xu, Q."Characterization of diethylnitrosamine-induced liver carcinogenesis in Syrian golden hamsters". Experimental and Therapeutic Medicine 3.2 (2012): 285-292.
Chicago
Chen, G., Dai, Z., Liang, R., Xiao, S., He, S., Zhao, H., Xu, Q."Characterization of diethylnitrosamine-induced liver carcinogenesis in Syrian golden hamsters". Experimental and Therapeutic Medicine 3, no. 2 (2012): 285-292. https://doi.org/10.3892/etm.2011.406